A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
← catalyst calendarNCT07493265 · readout in 178 d
Sponsored by Eisai Inc. (industry) · 4523.T — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
64estimated
Sites
57
Countries
Belgium, Canada, China +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-26 | actual | When the study began enrolling |
| Primary completion | 2027-02-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Narcolepsy
Interventions
- Drug: E2086
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline to Week 4 in MSL for E2086 Compared With Placebo Across Four MWTs in Participants With NT1 and NT2
measured Baseline and Week 4
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed